Jean-Yves Gillon

8PUBLICATIONS
32CO-AUTHORS
Pharmaceutical delivery technologiesPharmacogenomicsBiologically active moleculesBiomaterialsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 14, 2026
Translational Pharmacokinetic-Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI-6148 for the Treatment of Cutaneous Leishmaniasis.

Rasmus Hansen Henninger, Wietse M Schouten, Byron Arana

|Feb 27, 2026
Evaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants.

Alison Luckey, Kajal B Larson, Noha Rayad

|Nov 20, 2025
Safety, tolerability and pharmacokinetics of DNDI-6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants.

Jean-Yves Gillon, Sophie Delhomme, Delphine Launay

|Sep 22, 2025
Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans.

Jean-Yves Gillon, François Simon, Sharan Sidhu

|Feb 25, 2025
Model-Informed Drug Development of a Sustained Release Formulation of Flucytosine in the Treatment of Cryptococcal Meningitis: A Case Study Using Physiologically Based Pharmacokinetic Modeling.

Johanna Eriksson, Erik Sjögren, Jean-Yves Gillon

|Sep 18, 2024
Bioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitis.

Nabila Ibnou Zekri Lassout, Vishal Goyal, Edrich Krantz

Pageof 2

Frequent Collaborators

3 joint publications

Isabela Ribeiro

3 joint publications

Henri Caplain

3 joint publications

Vishal Goyal

3 joint publications

Francois Simon